Hulk Hogan, wrestling icon, dies at 71 in Florida home
Monday, Stifel analysts confirmed their Buy rating on Becton Dickinson (NYSE:BDX) shares with a steadfast price target of $224. Following a recent investor lunch in New York with Becton Dickinson’s top executives, the analysts have expressed a renewed confidence in the company’s prospects. The event featured Chairman, CEO, and President Tom Polen, along with Treasurer & Head of Investor Relations Greg Rodetis and Senior IR Director Adam Reiffe.
During the meeting, CEO Tom Polen addressed the results of the mixed fiscal second quarter of 2025, which ended in March. The period was marked by macroeconomic challenges leading to an unexpected dip in sales and a revision of the organic growth forecast. Despite these hurdles and ongoing investor concerns regarding the impending separation of the Biosciences & Diagnostic Solutions division, the management team provided a convincing outlook for the company’s future improvement.
The analysts highlighted that the headwinds from China, Pharmaceutical (TADAWUL:2070) Systems, and Life Sciences segments, which collectively affected fiscal years 2024 and 2025 by approximately 140-180 basis points, are expected to diminish over time. This anticipated easing of challenges is seen as a positive indicator for Becton Dickinson’s fundamental performance moving forward.
Moreover, while no new details were disclosed about the separation of the Biosciences & Diagnostic Solutions business, CEO Polen reassured that the evaluation process for the transaction is progressing as planned. The separation is a significant event for the company and has been closely watched by investors.
The analysts’ reiterated rating and price target reflect their belief in Becton Dickinson’s capacity to navigate through the current challenges and emerge with stronger fundamentals. The meeting with the company’s executives provided valuable insights into the strategies and initiatives that are expected to drive Becton Dickinson’s growth in the near future.
In other recent news, Becton Dickinson reported second-quarter revenues of $5.27 billion, slightly below the consensus estimate of $5.35 billion. The company’s earnings per share (EPS) for the quarter was $3.35, surpassing the consensus estimate of $3.28. Becton Dickinson has adjusted its fiscal year 2025 guidance, lowering its organic sales growth forecast to 3-3.5% and revising its EPS guidance to a range of $14.06 to $14.34. Jefferies analyst Matthew Taylor reduced the price target for Becton Dickinson to $255, maintaining a Buy rating, citing the challenging quarter and tariff uncertainties. Citi analysts downgraded Becton Dickinson from Buy to Neutral, reducing the price target to $185, due to the complexity of predicting performance factors. Barclays (LON:BARC) analysts lowered their price target to $241, maintaining an Overweight rating, and adjusted sales and EPS estimates due to foreign exchange headwinds and tariffs. Stifel reiterated a Buy rating with a $224 price target, following positive comments from the CEO regarding the outlook and business separation plans. The company is proceeding with the separation of its Biosciences unit, which is expected to impact its financial landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.